Patents Assigned to Quercegen Pharma
  • Smallpox monoclonal antibody
    Patent number: 7811568
    Abstract: Humanized monoclonal antibodies against the vaccinia virus B5R surface antigen. The antibodies are effective in treating smallpox infection. Also disclosed are nucleic acids that encode the heavy and light chains of such antibodies and cells that express them.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: October 12, 2010
    Assignee: Quercegen Pharma
    Inventors: Jean-Pierre Kinet, Marie-Helene Jouvin